Search Clinical Trials
Sponsor Condition of Interest |
---|
Measuring Brain Complexity to Detect and Predict Recovery of Consciousness in the ICU
Massachusetts General Hospital
Consciousness Disorders
Disorders of consciousness (DoC) caused by severe brain injury affect millions of people
worldwide each year. A patient's level of consciousness in the intensive care unit (ICU)
significantly impacts the recovery from disability and is a primary determinant of family
decisions about withdrawal of l1 expand
Disorders of consciousness (DoC) caused by severe brain injury affect millions of people worldwide each year. A patient's level of consciousness in the intensive care unit (ICU) significantly impacts the recovery from disability and is a primary determinant of family decisions about withdrawal of life-sustaining therapy (WLST). However, reliable assessment of consciousness in the ICU remains elusive. Transcranial magnetic stimulation-electroencephalography (TMS-EEG) is a tool that has shown the best performance in detecting signs of consciousness in patients with chronic DoC. The goals of this prospective, observational study are to demonstrate the diagnostic performance and prognostic utility of TMS-EEG in the ICU setting. Type: Interventional Start Date: Nov 2024 |
A Retrospective and Prospective Natural History of Genetic Vasculopathies
Massachusetts General Hospital
Multisystemic Smooth Muscle Dysfunction Syndrome
ACTA2
This study will combine retrospective review of medical records from patients with ACTA2
and ongoing collection of clinical data using standardized instruments and intervals on
an observational basis from patients with ACTA2.
Patients in cohorts 1-3 will be asked to attend clinic visits in person1 expand
This study will combine retrospective review of medical records from patients with ACTA2 and ongoing collection of clinical data using standardized instruments and intervals on an observational basis from patients with ACTA2. Patients in cohorts 1-3 will be asked to attend clinic visits in person per the schedule of events. At minimum, the medical records of patients with ACTA2 will be reviewed to record data on aspects of the disease, including disease characteristics and developmental milestones. The study is planned to enroll a total of 100 patients: 7 in cohort 1, 7 in cohort 2, and the remaining in cohorts 3 and 4. This study is planned to study patients for at least 3 years with the option to continue as long as possible for assessment of disease progression. During their continued study participation, as patients age, they may move into the next cohort. Beyond 3 years the duration of the study with be determined by availability of funding from sponsors. Type: Observational Start Date: May 2024 |
Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients
Massachusetts General Hospital
Insomnia
Postoperative Delirium
Delayed Neurocognitive Recovery
Postoperative Neurocognitive Disorder
The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST)
is a pilot randomized, controlled, singled-blinded (participant) trial in major
orthopedic joint surgery patients that will build on a previously clinically tested
cognitive behavioral therapy for insomnia (CB1 expand
The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST) is a pilot randomized, controlled, singled-blinded (participant) trial in major orthopedic joint surgery patients that will build on a previously clinically tested cognitive behavioral therapy for insomnia (CBT-I) mobile application paired with a wearable device (wrist actigraphy). Type: Interventional Start Date: Jan 2025 |
Developing a Peer Support Intervention for Depression in SCD
Massachusetts General Hospital
Subjective Cognitive Decline
Depression in Old Age
The purpose of this study is to assess the feasibility, acceptability, and fidelity of an
8-week intervention where peer coaches will deliver depression care to adults 60 years of
age or older who have depression and subjective cognitive decline. expand
The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline. Type: Interventional Start Date: May 2024 |
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
Noema Pharma AG
Tourette Syndrome
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on
reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will
be enrolled after a sentinel cohort of adults is complete. expand
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete. Type: Interventional Start Date: Sep 2024 |
Resilient Families
Massachusetts General Hospital
Parents
The goal is to develop, refine, and test the feasibility and acceptability of a dyadic,
resiliency intervention ("Resilient Families;" R-FAM) that aims to reduce emotional
distress and improve relationships among parents in the Neonatal Intensive Care Unit
(NICU). To achieve this goal, my aims are1 expand
The goal is to develop, refine, and test the feasibility and acceptability of a dyadic, resiliency intervention ("Resilient Families;" R-FAM) that aims to reduce emotional distress and improve relationships among parents in the Neonatal Intensive Care Unit (NICU). To achieve this goal, my aims are three-fold: (1) develop R-FAM using stakeholder input from interviews with parent dyads and focus groups with NICU staff; (2) optimize R-FAM through an open pilot with pre/post assessments and exit interviews; and (3) test R-FAM for feasibility and acceptability through a randomized clinical trial of R-FAM compared with a minimally enhanced usual control (MEUC). Type: Interventional Start Date: May 2025 |
Vagus Nerve Stimulation(VNS) As Treatment For Fibromyalgia Patients
Massachusetts General Hospital
Fibromyalgia
Fibromyalgia (FM) is a syndrome with clinical symptoms involving multiple systems. The
efficacy of current treatments is inadequate, and more alternative modalities are needed
for the management of FM patients. The parasympathetic vagus nerve innervates and
integrates sensory, motor, and autonomic1 expand
Fibromyalgia (FM) is a syndrome with clinical symptoms involving multiple systems. The efficacy of current treatments is inadequate, and more alternative modalities are needed for the management of FM patients. The parasympathetic vagus nerve innervates and integrates sensory, motor, and autonomic systems and has been suggested to play a role in pain modulation. The role of vagus nerve stimulation (VNS) as a treatment option for FM patients is yet to be investigated. The investigators propose to examine the hypothesis that vagus nerve stimulation could improve pain and related comorbid symptoms for FM patients. Type: Interventional Start Date: Jul 2024 |
Mucolipidosis Type IV Natural History Study
Massachusetts General Hospital
Mucolipidosis Type IV
The primary objectives of the study are: to describe the characteristics of the current
international MLIV population; to define the median age at which patients with MLIV
achieve or lose developmental milestones; to define the natural history of MLIV for the
Gross Motor Function Classification Sys1 expand
The primary objectives of the study are: to describe the characteristics of the current international MLIV population; to define the median age at which patients with MLIV achieve or lose developmental milestones; to define the natural history of MLIV for the Gross Motor Function Classification System (GMFCS) (Morris and Bartlett, 2004) and the MLIV specific scale and test the validity of retrospectively applying these scales to medical record data; to define the rate of visual decline in patients with MLIV. Type: Observational Start Date: Mar 2023 |
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
This is a first in human study in patients with advanced or metastatic solid tumors known
to have an MTAP deletion. The first part of the study is an open-label, dose escalation
and the second part is an open label dose expansion in specific MTAP-deleted tumor types.
The study drug, TNG462, is a se1 expand
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants. Type: Interventional Start Date: May 2023 |
Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behavio1
Massachusetts General Hospital
Suicide
Suicide, Attempted
The primary aim of this project are to evaluate a comprehensive, practice-ready, and
deployment-focused strategy for improving the prediction and prevention of suicide
attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern.
Our first aim is to evaluate the effects1 expand
The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. Our first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. We hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making. Type: Interventional Start Date: Feb 2025 |
CARv3-TEAM-E T Cells in Glioblastoma
Marcela V. Maus, M.D.,Ph.D.
Glioblastoma
Malignant Glioma
Recurrent Glioblastoma
Recurrent Glioma
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for
treating participants with glioblastoma.
The name of the treatment intervention used in this research study is:
-CARv3-TEAM-E T Cells (or Autologous T lymphocytes). expand
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes). Type: Interventional Start Date: Mar 2023 |
TriPRIL CAR T Cells in Multiple Myeloma
Marcela V. Maus, M.D.,Ph.D.
Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma
This research study involves the study of TriPRIL CAR T Cells for treating people with
relapsed or refractory multiple myeloma and to understand the side effects when treated
with TriPRIL CAR T Cells.
This research study involves the study drugs:.
- TriPRIL CAR T Cells
- Fludarabine and Cy1 expand
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. - TriPRIL CAR T Cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process Type: Interventional Start Date: Oct 2021 |
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Massachusetts General Hospital
Acute Myeloid Leukemia
This research is being done to assess the therapeutic activity of a promising combination
(azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in
induction-eligible patients with acute myeloid leukemia.
This study involves the following:
- Venetoclax and azacitidine (investi1 expand
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: - Venetoclax and azacitidine (investigational combination) - Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care) Type: Interventional Start Date: May 2021 |
The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU
Massachusetts General Hospital
Feeding Patterns
Sleep
Glucose Intolerance
The purpose of this study is to determine whether modifying the timing of nutrition
support from overnight to daytime enhances sleep quality, preserves circadian rhythms,
and improves overall inflammation and cardiometabolic profiles in postoperative patients
in the cardiac surgical ICU on enteral1 expand
The purpose of this study is to determine whether modifying the timing of nutrition support from overnight to daytime enhances sleep quality, preserves circadian rhythms, and improves overall inflammation and cardiometabolic profiles in postoperative patients in the cardiac surgical ICU on enteral nutrition. Type: Interventional Start Date: Feb 2022 |
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
Advanced Solid Tumor
Diffuse Large B Cell Lymphoma
Lymphoma, T-Cell
Mesothelioma, Malignant
Prostatic Neoplasms, Castration-Resistant
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety,
tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in
patients with advanced solid tumors and lymphomas. expand
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas. Type: Interventional Start Date: Sep 2019 |
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Manuel Monreal
Venous Thromboembolism
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a
multidisciplinary Project initiated in march 2001 and consisting in obtaining an
extensive data registry of consecutive patients with venous thromboembolism.
The main objective is to provide information on the Internet1 expand
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy, extreme body weight, etc), with the purpose of decreasing mortality, frequency of thromboembolic recurrences as well as bleeding complications and arterial events. As an additional objective RIETE is also aimed to create predictive scores that help physicians to better identify patients with high risk of presenting some of these complications. The primary parameters recorded by the registry comprise details of each patient's clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome (during the first 3 months of therapy) of antithrombotic treatment. Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death. Type: Observational [Patient Registry] Start Date: Mar 2001 |
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans1
North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
The LCH-IV is an international, multicenter, prospective clinical study for pediatric
Langerhans Cell Histiocytosis LCH (age < 18 years). expand
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years). Type: Interventional Start Date: Nov 2016 |
Prospective Screening for Breast Cancer-related Lymphedema
Massachusetts General Hospital
Lymphedema
The primary objectives of this study are twofold: 1) to detect and determine the level of
symptoms, functional disability, and changes in quality of life that breast cancer
patients experience from changes in their arms during and after treatment for breast
cancer by collecting patient reported out1 expand
The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. Type: Observational Start Date: Aug 2009 |
Open Pilot Trial of a Mind-Body Intervention for Patients With Chronic Hip Pain
Massachusetts General Hospital
Hip Pain
Hip Pain Chronic
Mind-Body Therapies
The goal of this study is to conduct a feasibility open pilot study (N=5) of HIPS with
virtual exit interviews among adult patients with chronic hip joint-related pain (HRP).
We will use this mixed methods information to assess the feasibility, credibility, and
acceptability of the HIPS interventio1 expand
The goal of this study is to conduct a feasibility open pilot study (N=5) of HIPS with virtual exit interviews among adult patients with chronic hip joint-related pain (HRP). We will use this mixed methods information to assess the feasibility, credibility, and acceptability of the HIPS intervention and optimize the program and study methodology in preparation for a pilot feasibility randomized control trial (RCT). Deliverables: [1] Adapt and refine open pilot protocol, patient recruitment, provider training, and other study materials. [2] Assess the feasibility, acceptability, and credibility of HIPS in preparation for a future feasibility RCT. Type: Interventional Start Date: Apr 2025 |
Efficacy of Synchronous, Virtual Cognitive Behavioral Therapy for Insomnia Across Phases of Cancer1
Massachusetts General Hospital
Insomnia Chronic
This project is a single center, prospective randomized controlled trial (N=198)
primarily evaluating the efficacy of the Survivorship Sleep Program vs. Enhanced Usual
Care on insomnia severity among cancer survivors. The investigators will also examine
secondary outcomes associated with cancer-rel1 expand
This project is a single center, prospective randomized controlled trial (N=198) primarily evaluating the efficacy of the Survivorship Sleep Program vs. Enhanced Usual Care on insomnia severity among cancer survivors. The investigators will also examine secondary outcomes associated with cancer-related insomnia including subjective and objective sleep measures (i.e., sleep diaries, actigraphy), emotional distress, fatigue, and use of sleep medications. Notably, most CBT-I trials with cancer survivors who have completed primary treatment with curative intent (i.e., curvivors) but not those in treatment or living with metastatic cancer (i.e., metavivors). To enhance generalizability, this RCT will stratify enrollment by survivorship phase (1:1:1). This project in strengthened by partnerships with community organizations (SurvivorJourneys and Ellie Fund) and use of both quantitative (i.e., surveys, actigraphy) and qualitative methods (i.e., interviews) to inform considerations for future implementation. Collectively, the proposed project will yield multiple deliverables to innovate cancer survivorship care, namely an efficacious, virtually delivered intervention addressing chronic insomnia, one of the most deleterious concerns among the growing population of cancer survivors in the US. Findings will inform a future effectiveness trial and the expansion of the synchronous delivery of CBT-I to survivors across different phases of cancer survivorship. Type: Interventional Start Date: Jan 2025 |
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
Massachusetts General Hospital
Food Insecurity
Implementation Science
Diet, Healthy
Behavioral Economics
This is a cluster randomized controlled trial of 30 food pantries affiliated with the
Greater Boston Food Bank to test the use of behavioral economics (BE) tools to encourage
food pantries to implement the Supporting Wellness at Pantries (SWAP) program, with the
goal of fostering accurate use of SW1 expand
This is a cluster randomized controlled trial of 30 food pantries affiliated with the Greater Boston Food Bank to test the use of behavioral economics (BE) tools to encourage food pantries to implement the Supporting Wellness at Pantries (SWAP) program, with the goal of fostering accurate use of SWAP traffic light labels on pantry shelves and increasing the healthfulness of foods chosen by pantry clients. Primary outcomes will be assessed at 6 and 12 months to compare the implementation and effectiveness of the SWAP program in the intervention vs. control pantries. Type: Interventional Start Date: Oct 2024 |
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Sana Biotechnology
Lupus Erythematosus
Systemic Lupus Erythematosus
SLE (Systemic Lupus)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatous Polyangiitis
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary
clinical response, cellular kinetics and exploratory assessments for subjects with severe
autoimmune diseases. expand
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases. Type: Interventional Start Date: Apr 2024 |
Innovating CBT-I for Cancer Survivors: An Optimization Trial
Massachusetts General Hospital
Cancer Survivorship
Insomnia
The overall goal of this project is to conduct a factorial, randomized controlled trial
to optimize synchronous, virtual delivery of CBT-I for cancer survivors. The proposed
project will yield multiple deliverables to innovate cancer survivorship care, chiefly an
optimized, scalable, virtually-deli1 expand
The overall goal of this project is to conduct a factorial, randomized controlled trial to optimize synchronous, virtual delivery of CBT-I for cancer survivors. The proposed project will yield multiple deliverables to innovate cancer survivorship care, chiefly an optimized, scalable, virtually-delivered intervention that addresses chronic insomnia, one of the most deleterious concerns among the growing demographic of cancer survivors in the U.S. Findings will inform future considerations for delivering CBT-I to cancer survivors. Type: Interventional Start Date: Sep 2024 |
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
University of California, San Francisco
Neonatal Seizure
Hypoxic-Ischemic Encephalopathy
Stroke
Intracranial Hemorrhage
Epilepsy
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios
from the Neonatal Seizure Registry and participating site outpatient clinics that aims to
evaluate whether and how genes alter the risk of post-neonatal epilepsy among children
with acute provoked neonatal sei1 expand
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal epilepsy among children with acute provoked neonatal seizures. The researchers aim to develop prediction rules to stratify neonates into low, medium, and high risk for post-neonatal epilepsy based on clinical, electroencephalogram (EEG), magnetic resonance imaging (MRI), and genetic risk factors. Type: Observational [Patient Registry] Start Date: Aug 2022 |
Promoting Well-being and Health in Heart Failure
Massachusetts General Hospital
Heart Failure
Heart Failure NYHA Class I
Heart Failure NYHA Class II
Heart Failure NYHA Class III
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive
Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly
PP and health behavior text messages for a total of 24 weeks (with interactive,
algorithm-driven, goal-focused text messages1 expand
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks), compared to an attention-matched MI-based educational condition, in a randomized trial (NIH Stage II) of 280 patients with New York Heart Association class I-III Heart Failure (HF). Type: Interventional Start Date: Nov 2021 |
- Previous
- Next